

DEVELOPMENT AND VALIDATION OF AMYLMETACRESOL BY RP-HPLC METHOD AND QBD APPROACH**Poonam P. Waykar^{1*} and Rohit J. Bhor²**

¹Student, Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy, Pravaranagar, MH 413736.

²Assistant Professor, Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy, Pravaranagar, MH 413736.

Article Received on
26 January 2025,

Revised on 16 Feb. 2025,
Accepted on 06 March 2025

DOI: 10.20959/wjpr20256-35781

***Corresponding Author****Poonam P. Waykar**

Student, Department of
Pharmaceutical Chemistry,
Pravara Rural College of
Pharmacy, Pravaranagar,
MH 413736.

ABSTRACT

Amylmetacresol (AMC), a widely used antiseptic in throat lozenges, requires precise measurement to ensure quality and efficacy in pharmaceutical formulations. This review focuses on the development and validation of an RP-HPLC method for quantifying AMC, employing a Quality by Design (QbD) approach. The QbD framework emphasizes identifying Critical Quality Attributes (CQAs) and establishing a robust Design Space through systematic risk assessment techniques, such as Failure Mode and Effects Analysis (FMEA). The RP-HPLC method was optimized for chromatographic conditions, including column selection, mobile phase composition, and flow rate, ensuring high sensitivity and specificity. Validation parameters such as linearity, precision, accuracy, and specificity were rigorously evaluated according to ICH guidelines. The method demonstrated excellent linearity with R^2 values exceeding 0.99, precision with relative standard deviations below 2%, and accuracy within the acceptable

recovery range of 98-102%. Furthermore, the study highlights the importance of employing statistical tools for optimization and the need for ongoing stability studies to assess AMC's integrity under various conditions. By integrating QbD principles into the analytical method development process, this work contributes to enhanced quality assurance in the production of AMC-containing formulations, ultimately ensuring consumer safety and regulatory compliance. The findings underscore the potential for RP-HPLC combined with QbD to improve pharmaceutical analysis and facilitate the reliable delivery of therapeutic products.

KEYWORDS: Amylmetacresol, RP-HPLC, QbD, AMC, Method development, Pharmaceutical.

INTRODUCTION

Amylmetacresol (AMC), also known as 6-Pentyl-m-cresol, is an antiseptic compound primarily used in the treatment of infections affecting the mouth and throat.^[1] It is commonly found in over-the-counter lozenges, such as Strepsils and Cēpacol, which are formulated to alleviate symptoms of sore throat and minor infections like pharyngitis and gingivitis.^[1] The compound exhibits both antibacterial and antiviral properties, making it effective against a range of pathogens that may cause discomfort in the oral cavity.^[1,2] Its mechanism of action includes blocking sodium channels, similar to local anesthetics, which contributes to its pain-relieving effects.^[1,2]

The pharmacological profile of amylmetacresol reveals its rapid absorption and elimination from the body. Upon administration, it is metabolized into a carboxylic acid and subsequently excreted through the kidneys.^[3] This efficient metabolic pathway underscores its utility in symptomatic relief, as it acts quickly to mitigate discomfort associated with throat infections²⁴. The low toxicity of amylmetacresol, with an LD50 of 1500 mg/kg in rats, further supports its safety for use in various formulations.^[4]

In pharmaceutical applications, amylmetacresol is predominantly utilized in throat lozenges and sprays designed for symptomatic relief.^[1] The combination of amylmetacresol with other antiseptics, such as dichlorobenzyl alcohol, enhances its efficacy by providing a broader spectrum of antimicrobial activity. This synergistic effect not only helps in reducing the infectivity of viruses present in the throat but also alleviates symptoms associated with sore throat irritation.^[1]

The formulation of amylmetacresol in lozenges allows for localized delivery, ensuring that the active ingredient targets the affected area directly.^[5] This method of administration is particularly advantageous for patients experiencing mild to moderate throat discomfort, as it provides immediate relief while also contributing to the healing process by reducing inflammation.^[2]

Accurate measurement of amylmetacresol is crucial for ensuring the quality and efficacy of pharmaceutical products containing this active ingredient. Quality control processes must

adhere to stringent regulatory standards to guarantee that each batch meets specified criteria for potency, purity, and safety.^[6] Variability in concentration can lead to ineffective treatment or adverse effects; therefore, robust analytical methods are essential for monitoring these parameters throughout the product lifecycle.^[6]

Moreover, accurate quantification allows manufacturers to maintain consistency across different production batches, which is vital for consumer trust and regulatory compliance. Inaccurate measurements can result in product recalls or legal liabilities, emphasizing the need for reliable analytical techniques during both development and routine quality assurance testing.^[7]

Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) has emerged as a cornerstone technique in pharmaceutical analysis due to its high sensitivity and specificity.^[8] This method is particularly effective for separating and quantifying compounds like amylmetacresol within complex mixtures.^[8,9] RP-HPLC operates on the principle of partitioning compounds between a stationary phase (typically hydrophobic) and a mobile phase (usually aqueous), allowing for efficient separation based on polarity differences.^[10]

The significance of RP-HPLC lies not only in its ability to provide accurate quantitative data but also in its versatility across various applications within pharmaceutical research and development. It can be employed for stability testing, formulation development, and routine quality control assessments. The method's adaptability makes it suitable for analyzing a wide range of pharmaceutical compounds, including those with varying solubility profiles.^[10]

Previous studies on amylmetacresol

The analytical methods for amylmetacresol primarily include chromatographic techniques, particularly High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC).^[11] HPLC has been favored due to its sensitivity, specificity, and ability to separate compounds in complex matrices. For instance, a study highlighted the use of RP-HPLC for the simultaneous determination of amylmetacresol and DCBA in lozenge formulations.^[12] The method involved optimizing various parameters such as mobile phase composition, flow rate, and detection wavelength to achieve optimal separation and quantification.

Another significant method employed is GC, which has been used for identifying and quantifying amylmetacresol in lozenges. The retention time of amylmetacresol on

chromatograms was compared against standard solutions to ensure accuracy. These methods have been validated according to ICH guidelines, encompassing parameters such as linearity, precision, accuracy, specificity, and robustness.^[13]

Despite the advancements in analytical methodologies for amylmetacresol, several gaps remain in current research. One notable gap is the limited exploration of alternative analytical techniques that could offer enhanced sensitivity or faster analysis times. While RP-HPLC has been extensively validated, there is a need for comparative studies involving other techniques like Ultra-High-Performance Liquid Chromatography (UHPLC) or capillary electrophoresis.^[14]

Method development technique	Solvent used	Retention time (min)
RP-HPLC for simultaneous estimation of Dextromethorphan and Amylmetacresol ^[15]	Mixed phosphate buffer: Acetonitrile (50:50)	Dextromethorphan: 4.120, Amylmetacresol: 5.300
RP-HPLC with gradient elution ^[16]	Acetonitrile and water (1% trifluoroacetic acid)	Not specified
Isocratic RP-HPLC ^[17]	Acetonitrile and water	Not specified

Moreover, many studies focus on the quantification of amylmetacresol in isolation without considering its interactions with other excipients or active ingredients in formulations.^[1] This oversight can lead to inaccuracies in dosage forms where multiple active ingredients are present. Additionally, there is a lack of comprehensive stability studies under various environmental conditions that could affect the integrity of amylmetacresol in pharmaceutical products.

RP-HPLC Methodologies

Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) has become a cornerstone technique for analyzing pharmaceutical compounds due to its versatility and efficiency. The methodology typically involves a non-polar stationary phase with a polar mobile phase, allowing for effective separation based on hydrophobic interactions. For compounds similar to amylmetacresol, such as DCBA and hexylresorcinol, RP-HPLC has been utilized to achieve high-resolution separations.^[4,17]

In recent studies focusing on amylmetacresol and its combinations with other antiseptics, researchers have optimized various chromatographic parameters. These include selecting

appropriate column types (e.g., C18 columns), adjusting mobile phase pH and ionic strength, and employing gradient elution techniques to enhance separation efficiency.^[14] The use of UV detection at specific wavelengths corresponding to the maximum absorbance of the analytes has also been a common practice.

Method Development in RP-HPLC for Amylmetacresol

1. Selection of chromatographic conditions

The development of a robust RP-HPLC method for the analysis of Amylmetacresol involves careful selection of chromatographic conditions. Key parameters include the choice of column, mobile phase composition, and flow rate. The column selection is pivotal as it directly influences the separation efficiency and resolution of the analyte. Typically, C18 columns are favored due to their wide applicability and effectiveness in separating non-polar to moderately polar compounds. For instance, a Kromasil C18 column with dimensions 250 mm x 4.6 mm and particle size of 5 μ m is commonly used, providing a good balance between resolution and analysis time.^[18]

The mobile phase composition is another critical factor that affects the retention time and peak shape of Amylmetacresol. A common approach is to utilize a gradient elution system, which can enhance the separation of closely eluting peaks. For example, a combination of acetonitrile and triethylamine has been successfully employed in various studies, adjusting the pH to optimize the interaction between the analyte and stationary phase.^[19] The optimization of mobile phase components often involves testing several ratios to achieve the desired resolution and retention time.

Flow rate is also an essential parameter in method development. A typical flow rate for RP-HPLC ranges from 0.5 to 1.5 mL/min, depending on the column dimensions and mobile phase viscosity.^[20] A flow rate of 1 mL/min is frequently used as it balances analysis time with resolution. However, adjustments may be necessary based on preliminary results, as higher flow rates can lead to decreased retention times but may compromise resolution.^[21]

2. Optimization strategies employed

Optimization strategies in RP-HPLC method development often involve systematic approaches such as Design of Experiments (DoE) or Quality by Design (QbD) principles. These methodologies allow for a thorough investigation of how various factors influence chromatographic performance. For example, using a Box-Behnken design can help identify

critical factors affecting peak area, retention time, and resolution while minimizing experimental runs.^[22]

During optimization, parameters such as pH, ionic strength of the mobile phase, and temperature can be varied to assess their impact on separation efficiency. The robustness of the method is tested by deliberately varying these conditions to ensure consistent performance across different analytical runs. Additionally, software tools can be employed to model the relationship between these variables and their effects on chromatographic outcomes.^[23]

Another common strategy is to perform forced degradation studies to understand how Amylmetacresol behaves under various stress conditions (e.g., heat, light, oxidation). This information helps in establishing stability-indicating methods that can differentiate between the active ingredient and its degradation products.^[24]

Standard Preparation and Sample Analysis

The preparation of standards and samples is crucial for ensuring accurate quantification in RP-HPLC analysis. Standards should be prepared at known concentrations that cover the expected range of Amylmetacresol concentrations in samples. Typically, stock solutions are prepared by dissolving a precise amount of Amylmetacresol in a suitable solvent (e.g., methanol or acetonitrile) to achieve a concentration that allows for further dilutions.^[25]

For sample analysis, it is essential to follow consistent procedures to avoid variability. Samples may need to be diluted appropriately before injection into the HPLC system. This step ensures that the concentration falls within the linear range established during method validation. Filtration through a 0.45 µm membrane filter is often performed to remove particulate matter that could clog the column or interfere with detection.^[26]

Injection volumes typically range from 10 µL to 100 µL depending on the sensitivity required for detection and the concentration of Amylmetacresol in samples. Smaller injection volumes may enhance sensitivity but could lead to variability if not within optimal limits.^[27]

The run times for RP-HPLC methods can vary significantly based on method complexity but generally fall within 10-30 minutes for most analyses. Shorter run times are preferred for high-throughput environments; however, this must not compromise resolution or accuracy.^[28]

Developing an effective RP-HPLC method for Amylmetacresol requires meticulous attention to detail regarding chromatographic conditions such as column selection, mobile phase optimization, and flow rate adjustments. Employing systematic optimization strategies ensures robustness and reliability in method performance. Furthermore, standard preparation and sample analysis protocols are critical for achieving accurate results in quantitative assessments of Amylmetacresol in pharmaceutical formulations.^[12,28] By adhering to these principles, researchers can establish validated methods that meet regulatory standards while providing reliable data for quality control purposes.

Validation parameters

1. Linearity

Linearity refers to the ability of an analytical method to provide results that are directly proportional to the concentration of the analyte within a specified range. In HPLC, this is typically assessed by preparing a series of standard solutions at different concentrations and plotting the response (usually peak area or height) against concentration. The correlation coefficient (R^2) is calculated to determine how well the data fit a linear regression model. A value close to 1 indicates excellent linearity.^[29]

The range of linearity should encompass the expected concentration levels in actual samples. For effective validation, at least five concentration levels should be tested, spanning from the lower limit of quantitation (LOQ) to the upper limit of quantitation (ULOQ). The acceptance criteria for linearity often include R^2 values greater than 0.99 and a lack of significant deviation from linearity across the tested concentrations.^[29]

2. Precision

Precision is defined as the degree of agreement among individual test results when the procedure is applied repeatedly under prescribed conditions. It can be categorized into two types: intra-day precision and inter-day precision. Intra-day precision assesses repeatability by conducting multiple analyses on the same day, while inter-day precision evaluates reproducibility by analyzing samples on different days.

To validate precision, standard deviation (SD) or relative standard deviation (RSD) is calculated for each set of results. Typically, acceptance criteria for intra-day precision might require RSD values to be less than 2%, while inter-day precision might allow for slightly higher values depending on the method's complexity.^[29]

3. Accuracy

Accuracy reflects how close a measured value is to the true value or accepted reference value. It is often assessed through recovery studies, where known amounts of analyte are added to sample matrices and then analyzed using the HPLC method. The percentage recovery is calculated by comparing the measured concentration to the known concentration.^[29]

Acceptance criteria for accuracy usually require recovery values between 98% and 102% for most pharmaceutical applications. Bias assessment may also be performed by comparing results from the analytical method with those obtained from a validated reference method.

4. Specificity

Specificity is the ability of an analytical method to measure the analyte in the presence of other components such as excipients, impurities, or degradation products without interference. To establish specificity in HPLC methods, forced degradation studies are often conducted where samples are subjected to stress conditions (e.g., heat, light, pH changes) to generate potential degradation products.^[29]

The specificity validation study typically involves analyzing a placebo matrix (without active pharmaceutical ingredient) and comparing it against samples containing known amounts of analyte and potential impurities. The absence of co-eluting peaks in chromatograms indicates good specificity.

5. Robustness

Robustness evaluates how small variations in method parameters affect analytical results. This includes changes in factors such as mobile phase composition, flow rate, column temperature, and pH. A robust method should yield consistent results even when minor adjustments are made.^[29]

To assess robustness, deliberate variations are introduced into method conditions during validation studies. The impact on parameters like retention time, peak area, and resolution is analyzed. Acceptance criteria may vary based on specific method requirements but generally involve maintaining consistent performance within predefined limits.

Compliance with regulatory guidelines

Adherence to regulatory guidelines is paramount in method validation for pharmaceuticals. The ICH guidelines Q2(R1) provide a comprehensive framework outlining acceptable

practices for validating analytical procedures. These guidelines emphasize that validation should demonstrate that an analytical procedure is suitable for its intended purpose.^[30]

Before conducting any validation studies, it is essential to have an approved written protocol detailing objectives, methodologies, acceptance criteria, and responsibilities. Regulatory authorities such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) require that all validation efforts align with these guidelines to ensure compliance throughout drug development and marketing authorization processes.^[31]

Quality by Design (QbD)

Quality by Design (QbD) is a systematic approach to pharmaceutical development that emphasizes the importance of quality throughout the product lifecycle. By integrating quality into each stage of development, from research through manufacturing, QbD aims to ensure that products consistently meet predefined quality standards. This approach is built on scientific principles and risk management strategies, allowing for a more efficient and effective development process.^[32]

1. Implementation of QbD Principles

The implementation of QbD principles begins with a clear understanding of the Quality Target Product Profile (QTPP). This profile outlines the desired characteristics of the final product, including efficacy, safety, and quality attributes. The QTPP serves as a roadmap for development, guiding researchers in identifying Critical Quality Attributes (CQAs)—the physical, chemical, biological, or microbiological properties that must be controlled to ensure product quality. For instance, CQAs for a drug might include its potency, purity, and stability.^[33]

Once CQAs are identified, the next step involves understanding the relationship between these attributes and various formulation and process variables. This understanding is crucial for establishing Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs). CMAs are the properties of raw materials that can affect CQAs, while CPPs are the parameters within the manufacturing process that must be controlled to ensure consistent product quality. By linking CMAs and CPPs to CQAs, developers can create a robust framework for monitoring and controlling quality throughout production.^[33]

2. Risk assessment techniques

To effectively manage risks associated with variability in materials and processes, QbD employs various risk assessment techniques. One commonly used method is Failure Mode and Effects Analysis (FMEA). FMEA is a structured approach that identifies potential failure modes within a process or product design and assesses their impact on overall quality. By prioritizing risks based on their severity and likelihood of occurrence, FMEA enables teams to focus their efforts on mitigating the most critical issues.^[34]

Another risk assessment tool often utilized in QbD is Design of Experiments (DoE). DoE allows researchers to systematically investigate the effects of multiple variables on CQAs by varying conditions in a controlled manner. This statistical approach not only helps in identifying optimal conditions for manufacturing but also provides insights into interactions between different parameters that may influence product quality.

3. Design space establishment

A key component of QbD is the establishment of a Design Space—the multidimensional region defined by acceptable ranges of CMAs and CPPs that ensure CQAs are consistently met. The Design Space is determined through extensive experimentation and data analysis, often employing multivariate statistical methods to evaluate how variations in input parameters affect output quality.^[34]

4. Parameters influencing product quality

Several parameters influence product quality within the QbD framework. These include raw material characteristics (such as particle size distribution or moisture content), formulation variables (like excipient type and concentration), and processing conditions (including temperature, pressure, and mixing speed). Understanding how these factors interact is essential for establishing robust manufacturing processes that consistently produce high-quality products.^[35]

5. Statistical tools employed for optimization

Statistical tools play a crucial role in optimizing processes under the QbD paradigm. In addition to DoE, other methods such as regression analysis and multivariate data analysis are commonly used to analyze complex datasets generated during experimentation. These tools help identify relationships between input variables and output responses, enabling developers to refine their processes based on empirical evidence.^[35]

CONCLUSION

The development and validation of Amylmetacresol using the RP-HPLC method and Quality by Design (QbD) principles represent a significant advancement in pharmaceutical analysis. By systematically identifying Critical Quality Attributes (CQAs) and employing rigorous risk assessment techniques like FMEA, researchers can ensure the reliability and consistency of Amylmetacresol formulations. Establishing a well-defined Design Space allows for flexibility in manufacturing while maintaining product quality. The integration of statistical tools for optimization further enhances the robustness of the analytical method, ensuring compliance with regulatory standards. Ultimately, this comprehensive approach not only improves the efficacy and safety of Amylmetacresol but also reinforces consumer trust in pharmaceutical products.

REFERENCES

1. Morokutti-Kurz M, Graf C, Prieschl-Grassauer E. Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat. *International Journal of General Medicine*, 2017; 28, 10: 53–60.
2. Tan TW, Chen BC, Tan HL, Chang CM. Effectiveness of amylmetacresol and 2,4-dichlorobenzyl alcohol throat lozenges in patients with acute sore throat due to upper respiratory tract infection: a systematic review protocol. *JBIC Evidence Synthesis*, 2017; 15(4): 862.
3. Surboyo MDC, Ernawati DS, Parmadiati AE. Glossitis Mimicking Median Rhomboid Glossitis Induced by Throat Lozenges and Refreshment Candies. *Journal of International Oral Health*, 2019; 11(5): 323.
4. Weckmann G, Hauptmann-Voß A, Baumeister SE, Klötzer C, Chenot JF. Efficacy of AMC/DCBA lozenges for sore throat: A systematic review and meta-analysis. *Int J Clin Pract*, 2017; 71(10).
5. Matthews D, Atkinson R, Shephard A. Spectrum of bactericidal action of amylmetacresol/2,4-dichlorobenzyl alcohol lozenges against oropharyngeal organisms implicated in pharyngitis. *Int J Gen Med*, 2018; 28, 11: 451–6.
6. Zhang L, Mao S. Application of quality by design in the current drug development. *Asian Journal of Pharmaceutical Sciences*, 2017; 1, 12(1): 1–8.
7. Hussain MK, Ashok MPK, Dhanola S. PHARMACEUTICAL CONCURRENT PROCESS VALIDATION OF AMYLMETACRESOL AND 2, 4-DICHLORO BENZYL

- ALCOHOL LOZENGES. In: JETIR [Internet], 2022 [2025; 1]. Available from: <https://www.jetir.org/view?paper=JETIR2208211>
8. Aguilar MI. Reversed-Phase High-Performance Liquid Chromatography. In: Aguilar MI, editor. HPLC of Peptides and Proteins: Methods and Protocols [Internet]. Totowa, NJ: Springer New York, 2004 [2025; 1]: 9–22. Available from: <https://doi.org/10.1385/1-59259-742-4:9>
 9. Shishov A, Nechaeva D, Moskvina L, Andrush V, Bulatov A. Automated solid sample dissolution coupled with sugaring-out homogenous liquid-liquid extraction. Application for the analysis of throat lozenge samples. *Journal of Molecular Liquids*, 2017; 1, 233: 149–55.
 10. Jayasree M, Chengalva P, Aruna G. Novel Liquid Chromatographic Method for the Simultaneous Estimation of Dextromethorphan and Amylmetacresol. *International Journal of ChemTech Research*, 2018; 1, 11: 141–7.
 11. Gómez-Canela C, Sala-Comorera T, Pueyo V, Barata C, Lacorte S. Analysis of 44 pharmaceuticals consumed by elderly using liquid chromatography coupled to tandem mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis*, 2019; 10, 168: 55–63.
 12. Thomas MJ. Amylmetacresol and 2, 4-dichlorobenzyl alcohol lozenges were better than placebo lozenges for relief of acute sore throat. *Ann Intern Med*, 2010; 17, 153(4): JC2-6.
 13. Dhir NK, Mishra T, Kaur V. Improved Analytical Method for Dichlorobenzaldehyde Impurity Detection in Lozenges by Convergence Chromatography. *Asian Journal of Pharmaceutical Research and Health Care*, 2018; 1, 10(1): 21–9.
 14. Khan H. UHPLC-MS/MS Technique: Applications in Analytical Chemistry. *Asian Journal of Chemistry*, 2024; 30, 36: 766–78.
 15. Jayasree M, Chengalva P, Aruna G. Novel Liquid Chromatographic Method for the Simultaneous Estimation of Dextromethorphan and Amylmetacresol. *International Journal of ChemTech Research*, 2018; 1, 11: 141–7.
 16. Pabale N, Shelke M, Bhagat V, Kamble T, Khatke M. A Review on HPLC Method Development and Validation. *International Journal of Pharmaceutical Sciences*, 2024; 28, 02(11): 1–1.
 17. Shabir G. HPLC Method Development and Validation for Pharmaceutical Analysis, 2004; 1 [2025; 1], 16. Available from: <https://www.pharmtech.com/view/hplc-method-development-and-validation-pharmaceutical-analysis>

18. Ruiz-Angel MJ, Pous-Torres S, Carda-Broch S, García-Alvarez-Coque MC. Performance of different C18 columns in reversed-phase liquid chromatography with hydro-organic and micellar-organic mobile phases. *Journal of Chromatography A*, 2014; 30, 1344: 76–82.
19. Armstrong DW, Chen S, Chang C, Chang S. A New Approach for the Direct Resolution of Racemic Beta Adrenergic Blocking Agents by HPLC. *Journal of Liquid Chromatography*, 1992; 1, 15(3): 545–56.
20. Guillaume YC, Peyrin E. Optimising mobile phase composition, its flow-rate and column temperature in HPLC using taboo search. *Talanta*, 2000; 6, 51(3): 579–86.
21. Yandamuri N. Comparative Study of New Trends in HPLC: A Review. *International Journal of Pharmaceutical Sciences Review and Research* [Internet]. [2025; 1]. Available from:
https://www.academia.edu/27042873/Comparative_Study_of_New_Trends_in_HPLC_A_Review
22. Özcan S, Levent S, Can NÖ. Quality by design approach with design of experiment for sample preparation techniques. *Advances in Sample Preparation*, 2023; 1, 7: 100079.
23. Rácz N, Molnár I, Zöldhegyi A, Rieger HJ, Kormány R. Simultaneous optimization of mobile phase composition and pH using retention modeling and experimental design. *Journal of Pharmaceutical and Biomedical Analysis*, 2018; 25, 160: 336–43.
24. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. *Journal of Pharmaceutical Analysis*, 2014; 1, 4(3): 159–65.
25. Kataoka H. Chapter 1 - Sample preparation for liquid chromatography. In: Fanali S, Chankvetadze B, Haddad PR, Poole CF, Riekkola ML, editors. *Liquid Chromatography (Third Edition)* [Internet]. Elsevier, 2023 [2025; 1]: 1–48. (Handbooks in Separation Science; vol. 2). Available from:
<https://www.sciencedirect.com/science/article/pii/B9780323999694000061>
26. Slack GC, Snow NH. 8 HPLC sample preparation. In: Ahuja S, Rasmussen H, editors. *Separation Science and Technology* [Internet]. Academic Press, 2007 [2025L 1]: 237–68. (HPLC Method Development for Pharmaceuticals; vol. 8). Available from:
<https://www.sciencedirect.com/science/article/pii/S0149639507800146>
27. Foster MD, Arnold MA, Nichols JA, Bakalyar SR. Performance of experimental sample injectors for high-performance liquid chromatography microcolumns. *Journal of Chromatography A*, 2000; 11, 869(1): 231–41.

28. El Deeb S, Preu L, Wätzig H. A strategy to develop fast RP-HPLC methods using monolithic silica columns. *Journal of Separation Science*, 2007; 30(13): 1993–2001.
29. Kumar D, Kumar A, Kumar V, Raj A, Rai R, Baliyan V, et al. A Comprehensive Review on Analytical Method Development using RP-HPLC and Recent Advances in Pharmaceutical Applications. *Journal for Research in Applied Sciences and Biotechnology*, 2023; 11, 2: 53–60.
30. ICH Q2(R2) Validation of analytical procedures - Scientific guideline | European Medicines Agency (EMA) [Internet], 2024 [2025; 1]. Available from: <https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline>
31. Protocol and Conduct. FDA [Internet], 2018; 3 [2025; 1]. Available from: <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/fda-bioresearch-monitoring-information/protocol-and-conduct>
32. Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J. Pharmaceutical product development: A quality by design approach. *Int J Pharm Investig*, 2016; 6(3): 129–38.
33. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding Pharmaceutical Quality by Design. *AAPS J*, 2014; 23, 16(4): 771–83.
34. Shah LA, Etienne A, Siadat A, Vernadat FB. A Process-Oriented Risk Assessment Methodology for Manufacturing Processes. *IFAC Proceedings Volumes*, 2013; 1, 46(9): 216–21.
35. Zhang L, Mao S. Application of quality by design in the current drug development. *Asian Journal of Pharmaceutical Sciences*, 2017; 1, 12(1): 1–8.